Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Avelo Airlines to End DHS Deportation Flights and Close Arizona Base Amid Rising Costs 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
MIGDAL HA'EMEQ, Israel, March 16, 2017 -- Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company"), a developer, manufacturer and marketer of innovative bio-active lipid-based nutritional ingredients and medical foods, today announced that that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2016 with the U.S. Securities and Exchange Commission (“SEC”). The annual report on Form 20-F, which contains audited financial statements, can be accessed on the SEC’s website at http://www.sec.gov as well as via the Company’s investor relations website at http://ir.enzymotec.com.
The Company will also deliver a hard copy of its annual report on Form 20-F, including its complete audited financial statements, free of charge, to its shareholders upon request to Oren Bryan at [email protected].
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies. For more information, visit www.enzymotec.com.
Company Contact Enzymotec Ltd. Oren Bryan Chief Financial Officer Phone: +972747177177 [email protected] Contact The Ruth Group Tram Bui / Lee Roth Phone: 646-536-7035 / 7012 [email protected] [email protected]
